Entrada Therapeutics

Entrada Therapeutics, Inc. operates as a biotechnology company. It focuses on delivery of biomolecules into the cell to treat devastating diseases. The firm offers intracellular enzyme replacement therapy and protein-protein interaction inhibitors programs. The company focuses on creating and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to target and engage underlying drivers of diseases. Entrada Therapeutics was founded by Dehua Pei in September 22, 2016 and is headquartered in Boston, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Entrada Therapeutics, Inc. (TRDA) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to earnings of $1.02 per share a year ago.

Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates

Entrada Therapeutics (TRDA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Here's Why Momentum in Entrada Therapeutics (TRDA) Should Keep going

– Additional positive data from the Company's completed Phase 1 clinical trial evaluating ENTR-601-44 reinforces its safety profile and supports the planned Q4 2024 global regulatory filings for a Phase 2 clinical trial – – Preclinical data presented for the first time, showing exon skipping and dystrophin production for ENTR-601-45, supports the planned Q4 2024 regulatory filings for a global direct-to-patient Phase 2 clinical trial – BOSTON, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. Today the Company announced the presentation of clinical and preclinical data in support of its expanding Duchenne clinical franchise at the 29th Annual Congress of the World Muscle Society in Prague, Czechia from October 8-12, 2024.

Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society

BOSTON, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines. Today, the Company announced that Natarajan Sethuraman, PhD, currently its Chief Scientific Officer, has been promoted to President of Research and Development, effective immediately.

Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development

BRISBANE, Calif.--(BUSINESS WIRE)--āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, today announced the appointment of Dipal Doshi to its Board of Directors. Mr. Doshi currently serves as Chief Executive Officer of Entrada Therapeutics (NASDAQ: TRDA). “Dipal is a seasoned leader with significant experience setting strategy and driving the operational and commercial growth of biopharmaceutical.

āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors

- Second annual DREAMS Grant Program awards $25,000 each to three U.S.-based non-profit organizations working to achieve greater equality for those living with Duchenne - - Announced in celebration of World Duchenne Awareness Day, grants are designed to fund efforts advancing diversity, equity, inclusion and accessibility within the Duchenne community - BOSTON, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible.

Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program

Entrada Therapeutics, Inc. (TRDA) came out with quarterly earnings of $1.55 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to loss of $0.78 per share a year ago.

Entrada Therapeutics, Inc. (TRDA) Tops Q2 Earnings and Revenue Estimates

The mean of analysts' price targets for Entrada Therapeutics (TRDA) points to a 25.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 25.73% Upside in Entrada Therapeutics (TRDA): Can the Stock Really Move This High?

Entrada Therapeutics (TRDA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Entrada Therapeutics (TRDA) Moves 10.4% Higher: Will This Strength Last?

Air Lease

Carvana

CVNA, AL and TRDA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 9, 2024.

Best Momentum Stocks to Buy for July 9th

American Public Education

Bumble

CVNA, TRDA, BMBL, APEI and AL have been added to the Zacks Rank #1 (Strong Buy) List on July 9, 2024.

New Strong Buy Stocks for July 9th

– The offering was led by a U.S.-based healthcare focused investor, two global mutual funds and Janus Henderson Investors, a global asset management firm – – The offering was led by a U.S.-based healthcare focused investor, two global mutual funds and Janus Henderson Investors, a global asset management firm –

Entrada Therapeutics Announces $100 Million Registered Direct Offering

– ENTR-601-44 was well-tolerated in healthy volunteers with no serious adverse events, no drug-related adverse events and no clinically significant changes or trends noted in vital signs, ECGs, physical exams or laboratory assessments –

Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy

BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced that Dipal Doshi, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL. The fireside chat will be held on Monday, June 10, 2024, at 4:00 p.m. Eastern Time.

Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference

The average of price targets set by Wall Street analysts indicates a potential upside of 37.1% in Entrada Therapeutics (TRDA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think Entrada Therapeutics (TRDA) Could Surge 37.08%: Read This Before Placing a Bet

BOSTON, May 16, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets long considered inaccessible. The Company today announced that Dipal Doshi, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ in New York, NY. The fireside chat will be held on Monday, May 20, 2024, at 9:30 a.m. Eastern Time.

Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

– Initiated dosing of the fourth and final cohort of Phase 1 clinical trial of ENTR-601-44 for the potential treatment of DMD with data readout on track for October of 2024 –

Entrada Therapeutics Reports First Quarter 2024 Financial Results

ACNB

Amphastar Pharma

ACNB, AMPH and TRDA have been added to the Zacks Rank #5 (Strong Sell) List on March 18, 2024.

New Strong Sell Stocks for March 18th

– Cash runway extended through the second quarter of 2026 – – $352 million in cash, cash equivalents and marketable securities as of December 31, 2023 – – Completed dosing for third cohort of Phase 1 clinical trial of ENTR-601-44 for the potential treatment of DMD with data readout on track for the second half of 2024 – – Regulatory applications expected in the fourth quarter of 2024 for the global Phase 2 clinical development of ENTR-601-44 and ENTR-601-45 in people living with DMD – BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company today reported financial results for the fourth quarter and full year ending December 31, 2023, and highlighted recent business updates.

Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced it will participate in the following two investor conferences:

Entrada Therapeutics to Present at Upcoming Investor Conferences

NEW YORK , Dec. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. ("Entrada" or the "Company") (NASDAQ: TRDA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Entrada Therapeutics, Inc. - TRDA

Despite providing additional information, the FDA declines to lift the clinical hold on Entrada's (TRDA) regulatory filing seeking approval to start studies on its DMD drug in the United States.

Entrada (TRDA) Down on FDA Maintaining Clinical Hold on DMD Drug

Entrada Therapeutics shares plummeted almost 30% after it announced that the U.S. Food and Drug Administration (FDA) has refused to lift its clinical hold on its Phase 1 study of its investigational therapeutic ENTR-601-44 for Duchenne muscular dystrophy.

Entrada Therapeutics shares tumble as FDA refuses to lift hold on muscular dystrophy trial

– Company completes dosing of first and second cohorts in Phase 1 clinical trial, ENTR-601-44-101 – – ENTR-601-44 clinical development program remains on track with data readout expected in second half of 2024 – – U.S. FDA clinical hold on IND application remains in effect – – Cash runway expected through 2025 – BOSTON, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the completion of dosing for the first and second cohorts of its Phase 1 clinical trial, ENTR-601-44-101. Entrada plans to announce data from ENTR-601-44-101 in the second half of 2024.

Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy

Entrada Therapeutics, Inc. (TRDA) came out with quarterly earnings of $1.02 per share, beating the Zacks Consensus Estimate of a loss of $0.55 per share. This compares to loss of $0.80 per share a year ago.

News for Entrada Therapeutics Stock (TRDA)